Skip to main content

Table 4 Dose reductions and attributed reasons for dose reductions of nal-IRI + 5-FU/LV

From: Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience

Number of dose reductions

N = 18 (%)

 1

15 (83)

 2

3 (17)

Reason attributed for dose

 Fatigue

8 (44)

 Diarrhea

8 (44)

 Nausea

2 (11)

 Neutropenia

2 (11)

 Anorexia

2 (11)

 Abdominal cramping

1 (6)

 Ageusia

1 (6)

 Not defined

1 (6)